Pharming Group N.V. announces that Pharming’s management will attend the following investor conferences in the month of June.
Pharming Group to attend the following Investor Conferences in June 2023 Read More »
ANGLE plc is delighted to announce that its first bespoke assay development customer, Artios Pharma, has signed a new contract to utilise two DNA Damage Response assays developed by ANGLE in a Phase 1 clinical trial expected to commence shortly.
Angle PLC Announces Pharma Services Contract with Artios Pharma Read More »
Accropeutics Bioscience announced that its oral small molecule TYK2/JAK1 inhibitor AC-201 has been approved by the Australian Human Research Ethics Committee to launch a clinical phase I trial in Australia.
BioInvent International AB and Transgene announce positive Phase 1a data on the oncolytic virus BT-001 for the treatment of solid tumors.
Biocept, Inc. announces the pricing of an underwritten public offering of 1,176,470 shares of its common stock and warrants to purchase up to an aggregate of 2,352,940 shares of its common stock at a combined offering price of $4.25 per share and an accompanying warrant to purchase two shares of common stock.
Biocept Announces Pricing of $5.0 Million Underwritten Public Offering Read More »
Transgene and BioInvent International AB announce positive Phase Ia data on the oncolytic virus BT-001 for the treatment of solid tumors.
Sensorion a pioneering clinical-stage biotechnology company which specializes in gene therapies in the inner ear, announces the results of resolutions presented at its Combined General Meeting, held on May 24, 2023, and made them available on the dedicated section of its website.
Sensorion Publishes Results of Combined Shareholders’ General Meeting Resolutions Read More »
Biophytis SA announces that it presented the positive results of the phase 2-3 COVA study with Sarconeos in severe COVID-19 at the American Thoracic Society International Conference that was held in Washington DC between the 19th and 24th of May 2023.
As federal aid expires, lower-income Americans — who saw the largest recent gains in uninsurance trends — will likely be affected the most, according to experts.
US projected to hit record-low uninsurance rate this year, before rates tick upward Read More »
Can Carl Icahn bend DNA-sequencing firm Illumina to his will? Shareholders will vote Thursday on removing Illumina’s CEO and chairman from the board and replacing them with nominees from the activist investor..
